Although biomarkers like PD-L1 expression and tumor mutation burden (TMB) have been shown to help predict immunotherapy efficacy, their effectiveness is also limited by the overlap between responders and non-responders, underscoring the necessity for more reliable biomarkers to guide clinical decisions (10–12). Here, CD274 is linked to neoplasm.